Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TVTX
TRAVERE THERAPEUTICS, INC.
NASDAQ
$65.67
▼ DOWN 2.74% (-1.85)

KEY STATISTICS

Market Cap$6.11 B
52w High$67.85
52w Low$17.27
Dividend Yield—
Frequency—
P/E-145.93
Volume808.19K
Shares Out.92.99M

COMPANY

LEADERSHIP

Eric Dube
CHIEF EXECUTIVE
Eric Dube

COMPENSATION 2026

Salary$854,250
Stock Awards$3,314,520
Incentive Plan Pay$964,125
All Other Comp.$14,872
Total$8,457,151

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 8, 2012
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
497

PRICE TARGET

Target High$78.00
Target Low$49.00
Target Median$67.00
Target Consensus$65.80

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$195.20M
OCT
29
THU

SPLIT RECORD

DATETYPERATIO
2012-11-02Reverse1:9
2009-07-02Reverse1:100

PRICE

$65.67 ▼ DOWN 2.74% (−$1.85)
OVERLAYS
$65.50$66.00$66.50$67.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM65.67

About Travere Therapeutics, Inc.

https://www.travere.com ↗

Travere Therapeutics, Inc. is a San Diego-based biopharmaceutical company developing and commercializing therapies for rare diseases, with marketed products like Chenodal, Cholbam, Thiola, and candidates in clinical trials.

INDUSTRY

Biotechnology

A PRODUCT TRAVERE THERAPEUTICS, INC. IS KNOWN FOR

FILSPARI® (sparsentan)
FILSPARI® (sparsentan)

FILSPARI, FDA-approved in February 2023, is the first non-immunosuppressive oral treatment for primary IgA nephropathy, driving recent revenue growth for Travere Therapeutics.

COMPETITORS

COMPETITOR
ARWR COMPARE
NVS COMPARE
VERA COMPARE
VRTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$113.15M $221.45M ▲$124.49M ▼$161.35M ▲
License$51.71M $3.08M ▼$2.71M ▼$8.23M ▲

Revenue by Geography

MapREGIONQ3-2025
NonUS$42.4M

ETFS HOLDING THIS STOCK

ETFS HOLDING
159
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.01% · 3.0M
XSU.TO
0.18% · 2.3M
XBI
1.28% · 2.3M
SCHA
0.13% · 442.0K
PJP
3.76% · 298.5K
FESM
0.24% · 237.3K
PSC
0.44% · 179.5K
FYC
0.78% · 167.2K
LFSC
8.60% · 165.9K
SBIO
3.12% · 114.6K
LABU
0.87% · 82.4K
XRSG.L
0.19% · 81.5K
GSSC
0.38% · 61.2K
BR
BRES
0.58% · 60.7K
RSSL
0.19% · 42.7K
FFTY
3.46% · 39.4K
BBP
1.59% · 28.1K
BBSC
0.24% · 26.7K
ETLI.DE
5.58% · 20.0K
SP
SPIT
3.14% · 16.3K
HELX
3.00% · 14.5K
FSCC
0.19% · 10.1K
ACSG
0.59% · 4.6K
URTY
0.07% · 3.6K
BKSE
0.26% · 3.5K
STXK
0.26% · 3.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
85.75%
HOLDERS
411
TOP 12 OF 411 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
11.4M sh · $339.25M
Fmr LLC
11.0M sh · $325.86M
Armistice Capital, LLC
8.9M sh · $131.36M
Blackrock, Inc.
8.1M sh · $193.6M
Blackrock Inc.
7.6M sh · $62.84M
Vanguard Group Inc
6.6M sh · $158.06M
Macquarie Group Ltd
5.0M sh · $119.13M
State Street Corp
5.0M sh · $147.36M
Bank Of America Corp /De/
4.6M sh · $259.53M
Perceptive Advisors LLC
4.3M sh · $163.47M
MM
Macquarie Management Holdings, Inc.
3.8M sh · $144.19B
Adage Capital Partners Gp, L.L.C.
3.6M sh · $84.89M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
LYONS GARY A
Purchase · 5.0K shares
2026-08-18
★
DIRECTOR
LYONS GARY A
Sale · 500 shares
2026-08-17
★
DIRECTOR
LYONS GARY A
Sale · 900 shares
2026-08-18
★
DIRECTOR
LYONS GARY A
Sale · 5.0K shares
2026-08-17

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OUTPERFORM 2
OVERWEIGHT 2
NEUTRAL 1
HOLD 1
11 GRADES IN THE LAST 12 MONTHS
Evercore ISI Group OUTPERFORM Canaccord Genuity BUY Wedbush OUTPERFORM Citigroup BUY Guggenheim BUY TD Cowen BUY Wells Fargo OVERWEIGHT HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
APGE$134.97COMPARE
CGON$74.34COMPARE
XENE$59.99COMPARE
CELC$88.44COMPARE
LEGN$19.88COMPARE
TARS$71.76COMPARE
IRON$80.03COMPARE
RARE$25.61COMPARE